Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tenofovir Disoproxil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 3/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | POLA1 | P09884 | 1/20 | 0.48 |
| ▸ | POLG | P54098 | 1/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenofovir Disoproxil SCHEMBL982493 | 0.97 | FAP (0.90) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL16628582 | 0.94 | FAP (0.92) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL29376425 | 0.93 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL18907027 | 0.93 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL52793 | 0.93 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL497677 | 0.93 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL20421896 | 0.93 | FAP (0.95) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL983652 | 0.93 | FAP (0.95) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL19031793 | 0.93 | FAP (0.98) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| SCHEMBL16486193 | 0.92 | FAP (0.93) | FAPCYP3A4CYP2D6ABCB11POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011506374-A | — | — | 2011-03-03 | — | — | JP | claimed |
| US-20110009368-A1 | SOLID FORMS OF TENOFOVIR DISOPROXIL | ULTIMORPHIX TECHNOLOGIES B.V. (NL) | 2011-01-13 | — | — | US | claimed |
| EP-2220098-A2 | SOLID FORMS OF TENOFOVIR DISOPROXIL | Ultimorphix Technologies B.v. (NL) | 2010-08-25 | — | — | EP | claimed |
| WO-2009074351-A2 | SOLID FORMS OF TENOFOVIR DISOPROXIL | ULTIMORPHIX TECHNOLOGIES B.V. (NL) | 2009-06-18 | — | — | WO | claimed |
| EP-2989111-A1 | NOVEL POLYMORPH OF TENOFOVIR DISOPROXIL MALEATE | Mylan Laboratories, Limited (IN) | 2016-03-02 | — | — | EP | disclosed |
| WO-2014184802-A1 | NOVEL POLYMORPH OF TENOFOVIR DISOPROXIL MALEATE | MYLAN LABORATORIES LTD (IN) | 2014-11-20 | — | — | WO | disclosed |
| US-20110009368-A1 | SOLID FORMS OF TENOFOVIR DISOPROXIL | ULTIMORPHIX TECHNOLOGIES B.V. (NL) | 2011-01-13 | — | — | US | disclosed |
| US-20110009368-A1 | SOLID FORMS OF TENOFOVIR DISOPROXIL | ULTIMORPHIX TECHNOLOGIES B.V. (NL) | 2011-01-13 | — | — | US | disclosed |
| CN-101918418-A | Solid forms of tenofovir disoproxil | ULTIMORPHIX TECHNOLOGIES B V | 2010-12-15 | — | — | CN | disclosed |
| CN-101918418-A | Solid forms of tenofovir disoproxil | ULTIMORPHIX TECHNOLOGIES B V | 2010-12-15 | — | — | CN | disclosed |
| EP-2220098-A2 | SOLID FORMS OF TENOFOVIR DISOPROXIL | Ultimorphix Technologies B.v. (NL) | 2010-08-25 | — | — | EP | disclosed |
| EP-2220098-A2 | SOLID FORMS OF TENOFOVIR DISOPROXIL | Ultimorphix Technologies B.v. (NL) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009074351-A3 | SOLID FORMS OF TENOFOVIR DISOPROXIL | ULTIMORPHIX TECHNOLOGIES B.V. (NL) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009074351-A2 | SOLID FORMS OF TENOFOVIR DISOPROXIL | ULTIMORPHIX TECHNOLOGIES B.V. (NL) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009074351-A2 | SOLID FORMS OF TENOFOVIR DISOPROXIL | ULTIMORPHIX TECHNOLOGIES B.V. (NL) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009368-A1 | SOLID FORMS OF TENOFOVIR DISOPROXIL | SORD, TYMS, TYMP | FAP 1678/4885CYP3A4 635/4885CYP2D6 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.